Travere Therapeutics, Inc. (TVTX)

Travere Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan 20, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	2,488	1,516	676	1,350	1,900	1,391
Market Cap Growth	83.01%	124.43%	-49.94%	-28.99%	36.59%	128.10%
Enterprise Value	2,569	1,641	446	1,251	1,609	1,177
Last Close Price	27.87	17.42	8.99	21.03	31.04	27.25
PS Ratio	5.59	6.50	4.65	12.33	14.42	7.02
PB Ratio	33.89	25.66	3.36	31.49	6.29	6.59
P/TBV Ratio	-	-	7.01	-	12.37	24.37
EV/Sales Ratio	5.89	7.04	3.07	11.43	12.21	5.93
Debt / Equity Ratio	4.48	6.80	2.02	9.51	0.87	1.16
Asset Turnover	0.84	0.34	0.20	0.15	0.19	0.33
Inventory Turnover	37.05	28.86	36.81	39.16	27.48	20.15
Quick Ratio	2.51	1.99	3.33	3.30	4.59	4.26
Current Ratio	2.75	2.08	3.47	3.42	4.70	4.43
Return on Equity (ROE)	-410.78%	-246.75%	-308.90%	-192.18%	-84.66%	-78.37%
Return on Assets (ROA)	-10.75%	-23.15%	-32.22%	-27.58%	-18.01%	-7.77%
Return on Invested Capital (ROIC)	-14.47%	-30.03%	-44.60%	-39.41%	-24.45%	-10.69%
Return on Capital Employed (ROCE)	-22.20%	-65.10%	-61.70%	-60.30%	-30.60%	-14.60%
Earnings Yield	-3.55%	-21.21%	-16.49%	-20.64%	-9.48%	-12.18%
FCF Yield	-2.36%	-15.66%	-41.45%	-13.80%	-1.05%	-3.56%
Buyback Yield / Dilution	-13.19%	-6.22%	-16.48%	-6.56%	-25.86%	-12.28%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q